Summary

Middle East AI in Oncology Market Trends

The Middle East AI in oncology market size was estimated at USD 111.33 million in 2024 and is projected to grow at a CAGR of 21.94% from 2025 to 2033. The rising prevalence of cancer, growing government initiatives, and technological advancements are significant factors contributing to market growth. Increasing cancer prevalence and growing awareness are boosting the demand for integrating AI-powered algorithms in their solutions. The incidence of cancer is rapidly increasing owing to various factors such as a sedentary lifestyle, poor eating habits, and physical inactivity. Rapid advancements in digital technology, owing to partnerships between government, industry players, and other investors in the healthcare ecosystem, are boosting the growth of the AI in oncology industry in Middle East.

For instance, according to an American Society of Clinical Oncology article published in January 2024, around 27,885 new cancer cases were reported in Saudi Arabia in 2020, and this figure is projected to surge to 60,429 by 2040, marking a significant increase of 116.7%. This sharp rise emphasizes the growing cancer burden in the country, driven by factors such as population growth and aging.

Middle East AI In Oncology Market Report Segmentation

This report forecasts revenue growth at regional and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the Middle East AI in oncology market report based on component, cancer type, application, end-use, and region:

• Component Outlook (Revenue, USD Million, 2021 - 2033)
• Software Solutions
• Hardware
• Services
• Cancer Type Outlook (Revenue, USD Million, 2021 - 2033)
• Breast Cancer
• Lung Cancer
• Prostate Cancer
• Colorectal Cancer
• Brain Tumor
• Other
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Diagnostics (Pathology, Cancer Radiology)
• Radiation therapy (Radiotherapy)
• Research & Development (Drug design, development process, etc.)
• Chemotherapy
• Immunotherapy
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Surgical Centers & Medical Institutes
• Others (Pharmaceutical companies, Research institutes & training centers)
• Country Outlook (Revenue, USD Million, 2021 - 2033)
• Saudi Arabia
• UAE
• Kuwait
• Qatar
• Oman

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Market Definitions
1.2.1. Component
1.2.2. Cancer Type Segment
1.2.3. Application Segment
1.2.4. End Use
1.3. Information analysis
1.3.1. Market formulation & data visualization
1.4. Data validation & publishing
1.5. Information Procurement
1.5.1. Primary Research
1.6. Information or Data Analysis
1.7. Market Formulation & Validation
1.8. Market Model
1.9. Total Market: CAGR Calculation
1.10. Objectives
1.10.1. Objective 1
1.10.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Insights Landscape
Chapter 3. Middle East AI in Oncology Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.2.3. Market opportunity analysis
3.2.4. Market challenges analysis
3.3. Middle East AI in Oncology Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.3.2.4. Environmental Landscape
3.3.2.5. Legal Landscape
3.3.2.6. Social Landscape
3.4. Health-tech Innovation Analysis
3.5. Case Studies
Chapter 4. Middle East AI in Oncology Market: Component Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Middle East AI in Oncology Market Component Movement Analysis
4.3. Middle East AI in Oncology Market Size & Trend Analysis, by Component, 2021 to 2033 (USD Million)
4.4. Hardware
4.4.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
4.5. Software Solutions
4.5.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
4.6. Services
4.6.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
Chapter 5. Middle East AI in Oncology Market: Cancer Type Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Middle East AI in Oncology Market Cancer Type Movement Analysis
5.3. Middle East AI in Oncology Market Size & Trend Analysis, by Cancer Type, 2021 to 2033 (USD Million)
5.4. Breast Cancer
5.4.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
5.5. Lung Cancer
5.5.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
5.6. Prostate Cancer
5.6.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
5.7. Colorectal Cancer
5.7.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
5.8. Brain Tumor
5.8.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
5.9. Others
5.9.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
Chapter 6. Middle East AI in Oncology Market: Application Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Middle East AI in Oncology Market Application Movement Analysis
6.3. Middle East AI in Oncology Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
6.4. Diagnostics
6.4.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
6.5. Radiation therapy
6.5.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
6.6. Research & Development
6.6.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
6.7. Chemotherapy
6.7.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
6.8. Immunotherapy
6.8.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
Chapter 7. Middle East AI in Oncology Market: End Use Estimates & Trend Analysis
7.1. Segment Dashboard
7.2. Middle East AI in Oncology Market End Use Movement Analysis
7.3. Middle East AI in Oncology Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
7.4. Hospitals
7.4.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
7.5. Surgical Centers & Medical Institutes
7.5.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
7.6. Others
7.6.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
Chapter 8. Middle East AI in Oncology Market: Regional Estimates & Trend Analysis
8.1. Regional Market Share Analysis, 2024 & 2033
8.2. Market Size & Forecasts Trend Analysis, 2021 to 2033
8.3. Middle East
8.3.1. Saudi Arabia
8.3.1.1. Key country dynamics
8.3.1.2. Regulatory framework
8.3.1.3. Competitive scenario
8.3.1.4. Saudi Arabia market estimates and forecasts, 2021 - 2033 (USD Million)
8.3.2. UAE
8.3.2.1. Key country dynamics
8.3.2.2. Regulatory framework
8.3.2.3. Competitive scenario
8.3.2.4. UAE market estimates and forecasts, 2021 - 2033 (USD Million)
8.3.3. Kuwait
8.3.3.1. Key country dynamics
8.3.3.2. Regulatory framework
8.3.3.3. Competitive scenario
8.3.3.4. Kuwait market estimates and forecasts, 2021 - 2033 (USD Million)
8.3.4. Qatar
8.3.4.1. Key country dynamics
8.3.4.2. Regulatory framework
8.3.4.3. Competitive scenario
8.3.4.4. Qatar market estimates and forecasts, 2021 - 2033 (USD Million)
8.3.5. Oman
8.3.5.1. Key country dynamics
8.3.5.2. Regulatory framework
8.3.5.3. Competitive scenario
8.3.5.4. Oman market estimates and forecasts, 2021 - 2033 (USD Million)
Chapter 9. Competitive Landscape
9.1. Company/Competition Categorization
9.2. Strategy Mapping
9.3. Company Market Position Analysis, 2024
9.4. Company Profiles/Listing
9.4.1. Lunit Inc.
9.4.1.1. Company overview
9.4.1.2. Financial performance
9.4.1.3. Product benchmarking
9.4.1.4. Strategic initiatives
9.4.2. Siemens Healthineers AG
9.4.2.1. Company overview
9.4.2.2. Financial performance
9.4.2.3. Product benchmarking
9.4.2.4. Strategic initiatives
9.4.3. GE HealthCare
9.4.3.1. Company overview
9.4.3.2. Financial performance
9.4.3.3. Product benchmarking
9.4.3.4. Strategic initiatives
9.4.4. NVIDIA Corporation
9.4.4.1. Company overview
9.4.4.2. Financial performance
9.4.4.3. Product benchmarking
9.4.4.4. Strategic initiatives
9.4.5. Roche
9.4.5.1. Company overview
9.4.5.2. Financial performance
9.4.5.3. Product benchmarking
9.4.5.4. Strategic initiatives
9.4.6. Insilico Medicine
9.4.6.1. Company overview
9.4.6.2. Financial performance
9.4.6.3. Product benchmarking
9.4.6.4. Strategic initiatives
9.4.7. Oracle
9.4.7.1. Company overview
9.4.7.2. Financial performance
9.4.7.3. Product benchmarking
9.4.7.4. Strategic initiatives
9.4.8. Intel Corporation
9.4.8.1. Company overview
9.4.8.2. Financial performance
9.4.8.3. Product benchmarking
9.4.8.4. Strategic initiatives